The regulator has made unapproved peptide products a priority compliance target. Its own wording is broad enough to raise hard questions for skincare — though how far that reach extends is far from settled. This analysis is interpretation, not legal advice — and on the cosmetics question, the regulator has not said as much as some commentary suggests. Where that gap exists, we flag it rather than paper over it.

The Therapeutic Goods Administration has escalated its scrutiny of peptide products, formally adding unapproved peptides to its priority compliance focus areas. In a media release dated 10 June 2026, the regulator pointed to rising unlawful importation, supply and advertising of products marketed largely for performance enhancement and anti-ageing.

The move follows a joint operation with the Australian Border Force and Victoria Police that seized peptides, performance and image enhancing drugs and illicit steroids with an estimated street value above $2 million. The TGA framed the change as a deliberate, intelligence-led response to a fast-moving market rather than a one-off crackdown.

Under the Therapeutic Goods Act 1989, the TGA treats peptide products as therapeutic goods. The framework draws one operative line: approved products, which are listed on the Australian Register of Therapeutic Goods (ARTG) and assessed for safety, quality and efficacy — insulin and GLP-1 medicines among them — and unapproved products, which are not listed and therefore not assessed at all.

Unapproved peptides remain therapeutic goods under the Act; they are simply non-compliant ones. The regulator’s concern is that consumers buying them — often from overseas websites, online platforms or social media — have no assurance about what is in the vial.

Here is where careful reading matters. The TGA’s notice that “peptide products are regulated as therapeutic goods” is unqualified — it does not carve out an exception by route of administration or for products labelled cosmetic. Some commentary takes that to its furthest logical end: that any topical cream containing a peptide is, by definition, an unapproved therapeutic good unless ARTG-listed.

That is a plausible inference. It is not, however, something the TGA has actually stated. The regulator says peptide products are therapeutic goods; it has not said that every cosmetic containing a peptide ingredient is captured, nor has it moved against mainstream peptide skincare. In Australian practice, the cosmetic–therapeutic boundary turns on presentation, claims, the specific ingredient and its scheduling — not on a blanket “peptide present, therefore therapeutic good” rule. Cosmetic peptides such as Argireline, Matrixyl and palmitoyl peptides have sat in ARTG-exempt skincare for years.

What genuinely pulls a topical peptide cream into therapeutic-goods territory tends to be three things: the specific peptide and its scheduling (a cream containing Schedule 4 BPC-157 is prescription-only no matter what the label says); therapeutic claims, explicit or implied, such as wound healing or tissue repair; and whether the ingredient appears on a relevant TGA determination. A peptide moisturiser claiming only to smooth and hydrate sits in a very different position from one marketed for “tissue repair.”

The honest bottom line: the cosmetic label is not an automatic safe harbour, but neither is a topical peptide cream automatically an unapproved therapeutic good. The real risk axis is the identity and scheduling of the specific peptide and the claims made around it — not the mere presence of “a peptide.” Anyone manufacturing, importing or selling such a product should treat 2026 as a tightening environment and get specific regulatory advice before relying on the cosmetic framing.